Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel
Herantis Pharma PlcCompany release, 2 June 2023 at 3:00 p.m. EEST The Board of Directors of Herantis Pharma Plc ("Herantis") has on 2 June 2023 decided on a new option rights program 2023 I. Under the new option rights program 2023 I, in aggregate up to 300,000 option rights entitling to shares may be issued to the CEO of Herantis, management team members, and other key personnel. The new option rights program is based on the authorization granted by the Annual General Meeting held on 20 April 2023. There is a weighty financial reason to issue the option rights as they will be offered